Replies to post #80351 on Anavex Life Sciences Corp (AVXL)

[plexrec]

Anavex is scheduled to present at 8:45 am on Dec.10 ----from the CTAD web-site ---OC60 - 9-Months and 12-Months Safety and Exploratory Efficacy Data of ANAVEX 2-73 in a Phase 2a Study
in Mild-to-Moderate Alzheimer’s Disease Patients
Stephen Macfarlane, MD1, Marco Cecchi, PhD2, Paul Maruff, PhD3, Kristina M Kapiak4, Christopher U Missling, PhD4
(1) Caulfield Hospital, Melbourne, Australia, (2) Neuronetrix, Louisville, KY, USA, (3) Cogstate Ltd., Melbourne, Australia, (4) Anavex Life Sciences Corp., New York,